S Winblad1,2, L Samuelsson3, C Lindberg2,3, G Meola4. 1. Department of Psychology, University of Gothenburg, Gothenburg, Sweden. 2. Neuromuscular Centre, Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden. 3. Department of Clinical Genetics, Sahlgrenska University Hospital, Gothenburg, Sweden. 4. Department of Biomedical Sciences for Health, IRCCS Policlinico San Donato, University of Milan, San Donato Milanese, Italy.
Abstract
BACKGROUND AND PURPOSE: Studies on cognitive decline in myotonic dystrophy type 1 (DM1) are characterized by conflicting results. The purpose of the present study was to analyse possible decline in classical/adult onset DM1 at a 5-year follow-up and to explore the correlation with disease-related and demographic factors. METHODS: Patients with DM1 (n = 37) were examined with a comprehensive neuropsychological test battery yielding measures on memory, attention, verbal, visuospatial and executive functions. Assessment of muscle impairment and CTG repeat expansion size was performed. RESULTS: A majority of the participants (65%) performed worse at follow-up. Compared to normative data, patients scored significantly worse on tests measuring memory, attention, visuospatial construction and verbal ability. Neither CTG repeat size nor muscle impairment related to cognitive decline. However, age at onset and disease duration were correlated with the number of tests in which performance was below 1 SD at both baseline and follow-up examination. CONCLUSIONS: Measurements show that classical/adult onset DM1 is characterized by cognitive decline. Both earlier onset and longer duration of the disease are indicative of more cognitive deficits.
BACKGROUND AND PURPOSE: Studies on cognitive decline in myotonic dystrophy type 1 (DM1) are characterized by conflicting results. The purpose of the present study was to analyse possible decline in classical/adult onset DM1 at a 5-year follow-up and to explore the correlation with disease-related and demographic factors. METHODS:Patients with DM1 (n = 37) were examined with a comprehensive neuropsychological test battery yielding measures on memory, attention, verbal, visuospatial and executive functions. Assessment of muscle impairment and CTG repeat expansion size was performed. RESULTS: A majority of the participants (65%) performed worse at follow-up. Compared to normative data, patients scored significantly worse on tests measuring memory, attention, visuospatial construction and verbal ability. Neither CTG repeat size nor muscle impairment related to cognitive decline. However, age at onset and disease duration were correlated with the number of tests in which performance was below 1 SD at both baseline and follow-up examination. CONCLUSIONS: Measurements show that classical/adult onset DM1 is characterized by cognitive decline. Both earlier onset and longer duration of the disease are indicative of more cognitive deficits.
Authors: Bryan P Fitzgerald; Kelly M Conn; Joanne Smith; Andrew Walker; Amy L Parkhill; James E Hilbert; Elizabeth A Luebbe; Richard T Moxley Journal: J Neurol Date: 2016-10-12 Impact factor: 4.849
Authors: Carla Ramon-Duaso; Thomas Gener; Marta Consegal; Cristina Fernández-Avilés; Juan José Gallego; Laura Castarlenas; Maurice S Swanson; Rafael de la Torre; Rafael Maldonado; M Victoria Puig; Patricia Robledo Journal: Cereb Cortex Date: 2019-07-05 Impact factor: 5.357
Authors: T Cabada; J Díaz; M Iridoy; P López; I Jericó; P Lecumberri; B Remirez; R Seijas; M Gomez Journal: Neuroradiology Date: 2020-11-25 Impact factor: 2.804
Authors: Gayle K Deutsch; Katharine A Hagerman; Jacinda Sampson; Gersham Dent; Jeanne Dekdebrun; Dana M Parker; Charles A Thornton; Chad R Heatwole; Sub H Subramony; Ami K Mankodi; Tetsuo Ashizawa; Jeffrey M Statland; W David Arnold; Richard T Moxley; John W Day Journal: Muscle Nerve Date: 2022-02-28 Impact factor: 3.852
Authors: Jacob N Miller; Alison Kruger; David J Moser; Laurie Gutmann; Ellen van der Plas; Timothy R Koscik; Sarah A Cumming; Darren G Monckton; Peggy C Nopoulos Journal: Front Neurol Date: 2021-07-01 Impact factor: 4.003
Authors: Edward Callus; Enrico G Bertoldo; Maria Beretta; Sara Boveri; Rosanna Cardani; Barbara Fossati; Elisa Brigonzi; Giovanni Meola Journal: Front Neurol Date: 2018-09-19 Impact factor: 4.003
Authors: Mark J Hamilton; John McLean; Sarah Cumming; Bob Ballantyne; Josephine McGhie; Ravi Jampana; Cheryl Longman; Jonathan J Evans; Darren G Monckton; Maria Elena Farrugia Journal: Front Neurol Date: 2018-10-02 Impact factor: 4.003